Skip to main content
NASDAQ:VTVT

vTv Therapeutics News Headlines

$2.47
+0.09 (+3.78 %)
(As of 05/18/2021 05:11 PM ET)
Add
Compare
Today's Range
$2.36
$2.53
50-Day Range
$2.27
$3.44
52-Week Range
$1.44
$4.75
Volume843,455 shs
Average Volume5.37 million shs
Market Capitalization$200.33 million
P/E RatioN/A
Dividend YieldN/A
Beta-2

Headlines

vTv Therapeutics (NASDAQ VTVT) News Headlines Today

SourceHeadline
VTv Therapeutics (VTVT) Reports Q1 Loss, Tops Revenue EstimatesVTv Therapeutics (VTVT) Reports Q1 Loss, Tops Revenue Estimates
finance.yahoo.com - May 5 at 9:52 PM
vTv Therapeutics Announces 2021 First Quarter Financial Results and Provides Corporate UpdatevTv Therapeutics Announces 2021 First Quarter Financial Results and Provides Corporate Update
finance.yahoo.com - May 5 at 4:48 PM
Short Interest in vTv Therapeutics Inc. (NASDAQ:VTVT) Rises By 138.2%Short Interest in vTv Therapeutics Inc. (NASDAQ:VTVT) Rises By 138.2%
americanbankingnews.com - April 29 at 1:28 AM
Contrasting MusclePharm (OTCMKTS:MSLP) and vTv Therapeutics (NASDAQ:VTVT)Contrasting MusclePharm (OTCMKTS:MSLP) and vTv Therapeutics (NASDAQ:VTVT)
americanbankingnews.com - April 25 at 10:16 PM
vTv Therapeutics Stock Is Believed To Be Significantly OvervaluedvTv Therapeutics Stock Is Believed To Be Significantly Overvalued
ca.finance.yahoo.com - April 15 at 11:00 PM
vTv Therapeutics (VTVT) Gets Breakthrough Tag for Diabetes DrugvTv Therapeutics (VTVT) Gets Breakthrough Tag for Diabetes Drug
finance.yahoo.com - April 14 at 1:09 PM
Analyzing The Price Action In vTv Therapeutics Stock TodayAnalyzing The Price Action In vTv Therapeutics Stock Today
benzinga.com - April 13 at 12:07 PM
TTP399 SimpliciT-1 Study Results to be presented at a scientific symposium in celebration of the 100th anniversary of the discovery of insulinTTP399 SimpliciT-1 Study Results to be presented at a scientific symposium in celebration of the 100th anniversary of the discovery of insulin
benzinga.com - April 12 at 4:48 PM
vTv Therapeutics Announces Issuance of U.S. Patent Covering Methods of Treatment Using TTP399vTv Therapeutics Announces Issuance of U.S. Patent Covering Methods of Treatment Using TTP399
finance.yahoo.com - March 23 at 11:43 AM
VTv Drop on New Product DevelopmentsVTv Drop on New Product Developments
baystreet.ca - March 19 at 1:30 PM
The Daily Biotech Pulse: Sarepta Gene Therapy Data, Idera Plunges On Failed Skin Cancer Study, 3 IPOsThe Daily Biotech Pulse: Sarepta Gene Therapy Data, Idera Plunges On Failed Skin Cancer Study, 3 IPOs
markets.businessinsider.com - March 19 at 8:30 AM
vTv Therapeutics Announces Initiation of Study Evaluating TTP399’s Potential to Reduce Risk of Diabetic Ketoacidosis in Patients with Type 1 DiabetesvTv Therapeutics Announces Initiation of Study Evaluating TTP399’s Potential to Reduce Risk of Diabetic Ketoacidosis in Patients with Type 1 Diabetes
finance.yahoo.com - March 19 at 3:29 AM
vTv Therapeutics to Present at the H.C. Wainwright Global Life Sciences ConferencevTv Therapeutics to Present at the H.C. Wainwright Global Life Sciences Conference
finance.yahoo.com - March 8 at 6:04 PM
How Much Are vTv Therapeutics Inc. (NASDAQ:VTVT) Insiders Spending On Buying Shares?How Much Are vTv Therapeutics Inc. (NASDAQ:VTVT) Insiders Spending On Buying Shares?
finance.yahoo.com - March 3 at 3:26 PM
vTv Therapeutics Announces 2020 Fourth Quarter and Full Year Financial Results and Provides Corporate UpdatevTv Therapeutics Announces 2020 Fourth Quarter and Full Year Financial Results and Provides Corporate Update
finance.yahoo.com - February 24 at 6:26 PM
vTv Therapeutics Announces Publication in Diabetes Care of Results from SimpliciT-1 Study of TTP399 in Patients with Type 1 DiabetesvTv Therapeutics Announces Publication in Diabetes Care of Results from SimpliciT-1 Study of TTP399 in Patients with Type 1 Diabetes
finance.yahoo.com - February 23 at 12:59 PM
vTv Therapeutics Announces Initiation of Multiple Ascending Dose Study of HPP737, an Oral PDE4 Inhibitor for the Treatment of PsoriasisvTv Therapeutics Announces Initiation of Multiple Ascending Dose Study of HPP737, an Oral PDE4 Inhibitor for the Treatment of Psoriasis
finance.yahoo.com - February 17 at 8:53 PM
vTv Therapeutics to Participate in the LifeSci Partners 10th Annual Healthcare Corporate Access Event VirtuallyvTv Therapeutics to Participate in the LifeSci Partners 10th Annual Healthcare Corporate Access Event Virtually
finance.yahoo.com - January 6 at 5:24 PM
vTv Therapeutics Inc. (NASDAQ:VTVT) Files An 8-K Unregistered Sales of Equity SecuritiesvTv Therapeutics Inc. (NASDAQ:VTVT) Files An 8-K Unregistered Sales of Equity Securities
marketwatch.com - December 18 at 12:41 AM
vTv Therapeutics Announces Topline Results of Phase 2 Elevage Study of Azeliragon in Patients with Mild Alzheimers Disease and Type 2 DiabetesvTv Therapeutics Announces Topline Results of Phase 2 Elevage Study of Azeliragon in Patients with Mild Alzheimer's Disease and Type 2 Diabetes
benzinga.com - December 15 at 7:52 PM
vTv Therapeutics Inc. (NASDAQ:VTVT) Files An 8-K Entry into a Material Definitive AgreementvTv Therapeutics Inc. (NASDAQ:VTVT) Files An 8-K Entry into a Material Definitive Agreement
marketwatch.com - December 15 at 7:52 PM
vTv Therapeutics Announces Topline Results of Phase 2 Elevage Study of Azeliragon in Patients with Mild Alzheimer’s Disease and Type 2 DiabetesvTv Therapeutics Announces Topline Results of Phase 2 Elevage Study of Azeliragon in Patients with Mild Alzheimer’s Disease and Type 2 Diabetes
finance.yahoo.com - December 15 at 7:52 PM
vTv Therapeutics Announces Licensing Agreement for Novel Nrf2 Activator to Anteris BiovTv Therapeutics Announces Licensing Agreement for Novel Nrf2 Activator to Anteris Bio
finance.yahoo.com - December 15 at 9:52 AM
Aditum Bio Announces Formation of Third Company, Anteris BioAditum Bio Announces Formation of Third Company, Anteris Bio
finance.yahoo.com - December 15 at 9:52 AM
Mid-Afternoon Market Update: Dow Turns Higher; Nabriva Therapeutics Shares SlideMid-Afternoon Market Update: Dow Turns Higher; Nabriva Therapeutics Shares Slide
benzinga.com - December 11 at 3:35 PM
Why vTv Therapeuticss Stock is Trading Higher TodayWhy vTv Therapeutics's Stock is Trading Higher Today
benzinga.com - December 11 at 3:35 PM
Stock Alert: VTv Therapeutics Nearly Doubles On Investment By MacAndrews & ForbesStock Alert: VTv Therapeutics Nearly Doubles On Investment By MacAndrews & Forbes
nasdaq.com - December 11 at 3:35 PM
vTv Therapeutics (VTVT) Shares March Higher, Can It Continue?vTv Therapeutics' (VTVT) Shares March Higher, Can It Continue?
finance.yahoo.com - December 2 at 5:23 PM
Where Do Hedge Funds Stand On vTv Therapeutics Inc (VTVT)?Where Do Hedge Funds Stand On vTv Therapeutics Inc (VTVT)?
finance.yahoo.com - November 28 at 10:57 PM
vTv Therapeutics raises $47M via stock purchase agreementvTv Therapeutics raises $47M via stock purchase agreement
seekingalpha.com - November 24 at 10:42 PM
vTv Therapeutics Announces Common Stock Purchase Agreement for up to $47 Million with Lincoln Park CapitalvTv Therapeutics Announces Common Stock Purchase Agreement for up to $47 Million with Lincoln Park Capital
finance.yahoo.com - November 24 at 5:42 PM
News for vTv Therapeutics Inc (A)News for vTv Therapeutics Inc (A)
markets.businessinsider.com - November 18 at 1:07 PM
vTv Therapeutics Announces 2020 Third Quarter Financial Results and UpdatevTv Therapeutics Announces 2020 Third Quarter Financial Results and Update
finance.yahoo.com - November 5 at 6:13 PM
VTv Therapeutics Elevage study suggests comparability to diabetes subgroup of Phase 3 STEADFAST studyVTv Therapeutics' Elevage study suggests comparability to diabetes subgroup of Phase 3 STEADFAST study
seekingalpha.com - November 4 at 9:27 AM
vTv Therapeutics Presents Baseline Characteristics of the Enrolled Subjects in the Elevage Study Suggesting Comparability to the Post-Hoc Diabetes Subgroup of the Phase 3 STEADFAST StudyvTv Therapeutics Presents Baseline Characteristics of the Enrolled Subjects in the Elevage Study Suggesting Comparability to the Post-Hoc Diabetes Subgroup of the Phase 3 STEADFAST Study
finance.yahoo.com - November 4 at 9:26 AM
Week Ahead In Pharma: COVID-19 Data Readout, FDA Decisions, CTAD PresentationWeek Ahead In Pharma: COVID-19 Data Readout, FDA Decisions, CTAD Presentation
nasdaq.com - November 1 at 7:36 AM
What Kind Of Shareholders Hold The Majority In vTv Therapeutics Inc.'s (NASDAQ:VTVT) Shares?What Kind Of Shareholders Hold The Majority In vTv Therapeutics Inc.'s (NASDAQ:VTVT) Shares?
finance.yahoo.com - October 29 at 2:55 PM
vTv Therapeutics to Present Study Update and Preliminary Data on Baseline Characteristics of Study Participants in Phase 2 Elevage Study Evaluating Azeliragon at 13th Clinical Trials on Alzheimer’s Disease (CTAD) Digital EventvTv Therapeutics to Present Study Update and Preliminary Data on Baseline Characteristics of Study Participants in Phase 2 Elevage Study Evaluating Azeliragon at 13th Clinical Trials on Alzheimer’s Disease (CTAD) Digital Event
finance.yahoo.com - October 29 at 8:26 AM
Board member resigns from High Point-based vTv Therapeutics after one monthBoard member resigns from High Point-based vTv Therapeutics after one month
bizjournals.com - October 9 at 9:53 AM
vTv Therapeutics Presents Additional Positive Clinical Study Results Supporting the Safety and Efficacy of TTP399 as Adjunctive Therapy in Patients with Type 1 DiabetesvTv Therapeutics Presents Additional Positive Clinical Study Results Supporting the Safety and Efficacy of TTP399 as Adjunctive Therapy in Patients with Type 1 Diabetes
benzinga.com - September 23 at 7:45 AM
vTv Therapeutics adds MacAndrews & Forbes EVP to boardvTv Therapeutics adds MacAndrews & Forbes EVP to board
bizjournals.com - September 18 at 8:41 AM
An In-Depth Look At vTv TherapeuticsAn In-Depth Look At vTv Therapeutics
seekingalpha.com - September 16 at 4:04 PM
vTv Therapeutics to Present Additional Positive Clinical Study Results from Phase 2 Simplici-T1 Study of TTP399 as Adjunctive Therapy for Patients with Type 1 Diabetes at EASD Virtual MeetingvTv Therapeutics to Present Additional Positive Clinical Study Results from Phase 2 Simplici-T1 Study of TTP399 as Adjunctive Therapy for Patients with Type 1 Diabetes at EASD Virtual Meeting
finance.yahoo.com - September 16 at 11:02 AM
vTv Therapeutics Announces Appointment of Edward P. Taibi to its Board of DirectorsvTv Therapeutics Announces Appointment of Edward P. Taibi to its Board of Directors
finance.yahoo.com - September 15 at 12:17 PM
vTv Therapeutics Inc. Class A Common Stock (VTVT)vTv Therapeutics Inc. Class A Common Stock (VTVT)
nasdaq.com - August 17 at 9:37 PM
vTv Therapeutics Announces 2020 Second Quarter Financial Results and UpdatevTv Therapeutics Announces 2020 Second Quarter Financial Results and Update
finance.yahoo.com - August 3 at 6:25 PM
vTv Therapeutics to Present Additional Clinical Data from the STEADFAST Study of Azeliragon at the Virtual Alzheimer's Association International ConferencevTv Therapeutics to Present Additional Clinical Data from the STEADFAST Study of Azeliragon at the Virtual Alzheimer's Association International Conference
finance.yahoo.com - July 27 at 9:03 AM
vTv Therapeutics TTP399 successful in mid-stage type 1 diabetes studyvTv Therapeutics' TTP399 successful in mid-stage type 1 diabetes study
seekingalpha.com - June 15 at 9:33 AM
vTv Therapeutics Presents Two Late-Breaking Poster Sessions on Simplici-T1 Study at the American Diabetes Association’s Virtual Sessions Supporting the Potential of TTP399 as First-in-Class Oral Adjunctive Therapy for Type 1 Diabetes PatientsvTv Therapeutics Presents Two Late-Breaking Poster Sessions on Simplici-T1 Study at the American Diabetes Association’s Virtual Sessions Supporting the Potential of TTP399 as First-in-Class Oral Adjunctive Therapy for Type 1 Diabetes Patients
finance.yahoo.com - June 13 at 12:46 PM
vTv Therapeutics Presents Two Late-Breaking Poster Sessions on Simplici-T1 Study at the American Diabetes Associations Virtual Sessions Supporting the Potential of TTP399 as First-in-Class Oral Adjunctive Therapy for Type 1 Diabetes PatientsvTv Therapeutics Presents Two Late-Breaking Poster Sessions on Simplici-T1 Study at the American Diabetes Association's Virtual Sessions Supporting the Potential of TTP399 as First-in-Class Oral Adjunctive Therapy for Type 1 Diabetes Patients
www.benzinga.com - June 13 at 12:36 PM
This page was last updated on 5/18/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.